| Name | MAGL-IN-4 |
|---|---|
| Synonyms |
His121 G57
7-Oxa-5-azaspirooctan-6-one, 2-[[3-[(3-chloro-4-methylphenyl)methoxy]-1-azetidinyl]carbonyl]-, cis cis-2-(3-((3-Chloro-4-methylbenzyl)oxy)azetidine-1-carbonyl)-7-oxa-5-azaspirooctan-6-one (2s,4s)-2-{3-[(3-chloro-4-methylphenyl)methoxy]azetidine-1-carbonyl}-7-oxa-5-azaspirooctan-6-one Monoacylglycerol lipase,CB1,lipase,monoacylglycerol,CB2,Inhibitor,inhibit,BBB,brier,MAGLIN4,MAGL IN 4,blood-brain,endocannabinoid,hERG,FAAH,2-AG,ABHD6,MAGL MAGL-IN-4, 10 mM in DMSO |
| Description | MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain[1]. |
|---|---|
| Related Catalog | |
| In Vitro | MAGL-IN-4 (compound 4f) shows a high LLE (5.9), a logD of 2.3 for MAGL[1]. MAGL-IN-4 exhibits no inhibition toward the closely related serine hydrolases (FAAH and ABHD6; all IC50>10000 nM). MAGL-IN-4 has no significant binding potentials to cannabinoid receptors (CB1: 19% and CB2: 5% at 10 μM), and low hERG liability (14.4% inh. at 10 μM, manual patch clamp, without BSA)[1]. |
| In Vivo | MAGL-IN-4 (compound 4f; 0.1-10 mg/kg; oral; single dose) results in a significant elevation in the level of 2-AG and reduction in that of arachidonic acid (AA) from 0.3 mg/kg in C57BL/6J mice[1]. |
| References |
| Molecular Formula | C18H21ClN2O4 |
|---|---|
| Molecular Weight | 364.82 |